Pharmaceutical Market Europe • March 2023 • 3
COMMENT
In-person conferences are back, but there is an urgency to reach a more diverse, inclusive audience through dynamic programmes and immersive technology. In Danny Buckland’s article, he looks at how companies are boosting their impact and engagement.
As Danny says: ‘Delegates have been flocking back to face-to-face congresses after the pandemic’s drought but hybrid events are becoming the norm by offering healthcare professionals, academia and industry staff the ability to attend or connect virtually and tailor their consumption.’
He goes on to say that while ‘there is little sign that in-person events are fading in popularity...the word ‘hybrid’ remains a focus as organisers seek to offer the best of both mediums’. Read more on page 28.
In our interview with Scott Curley, general manager of Amarin, UK and Ireland, he talks about the risks of cardiovascular disease (CVD) and the importance of getting the right treatment at the right time. In the article, he looks at the impact of the pandemic on care for patients with CVD, how the government and the NHS are working together to improve patient care, and the best steps patients can take to protect against an increased risk of CVD. Read more on page 16.
Looking ahead, our April issue will focus on the vital role of behavioural change in healthcare.
There is overwhelming evidence that small changes in health-related behaviour can have a significant impact on people’s health and life expectancy. In our next issue we will look at the challenges and benefits of implementing and maintaining behaviour change for both individuals and healthcare providers.
If you would like to make your voice heard on this topic, please get in touch at sales@pmlive.com
I hope you enjoy this issue!
Iona Everson
Group Managing Editor
Keep up to date with the latest developments in the UK and global healthcare marketplace – sign up to daily or weekly news alerts and fortnightly or monthly bulletins on specific topics at www.pmlive.com/register
THE TEAM
Editorial:
Group Managing Editor
Iona Everson
Journalist/editorial assistant
Emily Kimber
Studio:
Executive Director
Karl Equi
Sales:
Business Director
Tara Lovegrove
EDITORIAL ADVISORY BOARD
Philip Atkinson
Founder of Hive-Logic, Lifescience Transformation
Uday Bose
Corporate vice president, head of global marketing oncology, Boehringer Ingelheim
Dr Luc Hermans
VP commercial planning and operations Europe, Asia, Middle East, Gilead Sciences
Stefan Janssens
President EMEA, Cegedim Dendrite
John Morris
Partner, KPMG
Paul Pay
Chief business development officer, Norgine
Mark Rothera
Chief executive officer, Orchard Therapeutics
Ian Talmage
Senior vice president, global marketing, general medicine, Bayer Pharmaceuticals
PUBLISHED BY
PMGroup
Mansard House, Church Road, Little Bookham, Surrey, KT23 3JG, UK
Tel: +44 (0)1372 414200
Fax: +44 (0)1372 414201
CONTACT US
General enquiries: info@pmlive.com
Editorial: editor@pmlive.com
Advertising: sales@pmlive.com
Subscriptions: subscriptions@pmlive.com
Views expressed by the contributors do not necessarily represent those of the publisher, editor or staff.
© 2023 PMGroup
All rights reserved. No part of this publication may be copied, reproduced, transmitted, photocopied, recorded or stored on any retrieval system without the prior written consent of the publishers.
The magazine is also available at the following subscription rates: £120 UK, £180 Europe, £210 RoW